Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...
Zahi Touma, MD, PhD, from the University Health Network in Toronto, and colleagues examined whether anifrolumab plus SOC is associated with reduced organ damage accumulation compared with SOC only ...
A recent study evaluated the effectiveness of anifrolumab (Saphnelo®) combined with standard of care (SOC) treatments compared to SOC treatment alone in preventing organ damage. Results showed that ...
Overall, the trials showed that a once-monthly intravenous dose of anifrolumab was able to reduce disease activity across organ system in SLE, including skin and joints, and also helped patients ...
After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn ... Lupus is an autoimmune disease in which the immune system attacks healthy tissue in the body instead ...
The likelihood of experiencing an increase in Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index within 208 weeks was lower for patients in the ...
Hosted on MSN1mon
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback